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ABSTRACT 
Alosteric modulators of pentameric 
ligand gated ion channels (pLGICs) are thought 
to act on elements of the pathways that couple 
agonist binding to channel gating. Using α4β2 
nicotinic acetylcholine receptors (nAChRs) and 
the α4β2-selective positive modulators 17β-
estradiol (βEST) and desformylflustrabromine 
(dFBr), we have identified pathways that link the 
binding sites for these modulators to the Cys 
loop, a region that is critical for channel gating 
in al pLGICs. Previous studies have shown that 
the binding site for potentiating βEST is in the 
C-terminal (post-M4 region) of the α4 subunit. 
Here, using homology modeling in combination 
with mutagenesis and electrophysiology, we 
identified the binding site for potentiating dFBr 
on the top-half of a cavity between the third 
(M3) and fourth transmembrane (M4) α-helices 
of the α4 subunit. We found that the binding 
sites for βEST and dFBr communicate with the 
Cys loop, through interactions between the last 
residue of post-M4 and F170 of the conserved 
FPF sequence of the Cys loop, and that these 
interactions afect potentiating eficacy. In 
addition, interactions between a residue in M3 
(Y309) and F167, a residue adjacent to the Cys 
loop FPF motif, also afect dFBr potentiating 
eficacy. Thus, the Cys loop acts as a key control 
element in the alosteric transduction pathway 
for potentiating βEST and dFBr. Overal, we 
propose that positive alosteric modulators that 
bind the M3-M4 cavity or post-M4 region 
increase the eficacy of channel gating through 
interactions with the Cys loop. 
 
 The α4β2 nicotinic acetylcholine 
receptor (nAChR) belongs to the superfamily of 
pentameric ligand gated ion channels (pLGICs). 
In humans, this superfamily comprises the Cys 
loop receptors (including muscle and neuronal 
nAChRs, 5-HT3, GABAA, and glycine 
receptors), which mediate al fast central nervous 
system synaptic inhibition and much of fast 
peripheral excitation. Cys loop receptor subunits 
assemble as a pentamer of identical (homomeric 
channels) or diferent (heteromeric channels) 
subunits around a central ion channel. The 
individual subunits have a large extracelular N 
terminal domain (ECD) that consists of 10 β-
strands (β1-β10) folded into a β-sandwich, and a 
transmembrane domain (TMD) with four 
transmembrane α helices (M1 to M4) connected 
by linkers (M1-M2, M2-M3, M3-M4), as wel as 
intracelular domains and a highly variable 
extracelular C-terminal (post-M4) region (1). 
There are 2-5 neurotransmiter binding sites at 
subunit interfaces within the ECD, and these are 
functionaly coupled to the transmembrane ion 
channel located ca. 50 Å away. In the nAChR, 
the subunit contributing the principal face of the 
agonist binding site (an α subunit) couples 
agonist-triggered agonist binding site 
movements to channel gating (2, 3). The 
coupling is achieved at the ECD-TMD interface 
by a principal pathway that couples the pre-M1 
region in the ECD to the M2-M3 linker through 
the β1-β2 loop (4) and the canonical FPF motif 
of the β6-β7 loop (the Cys loop) (5, 6). More 
recently, it has been shown that gating is also 
afected by more peripheral pathways that 
couple M4 to M1 and M3 (7) and, post-M4 to 
the Cys loop (8). 
 Transduction pathways in α4β2 nicotinic receptor potentiation 
 
2 
 
 In common with al members of the 
pLGIC family, the curent responses of α4β2 
nAChR can be enhanced by a variety of agents, 
including Zn2+ (9, 10), the endogenous steroid 
17β-estradiol (βEST) (11), 
desformylflustrabromine (dFBr) (12, 13) and 
synthetic ligands CMPI (14), LY2087101 (15), 
and NS206 and NS9283 (16, 17). The 
identification of positive alosteric modulator 
(PAM) binding sites in the TMD of the α4 
subunit, e.g. βEST and NS206 binding sites (11, 
17), as wel as on the signature α4/α4 interface 
present in α4β2 nAChRs composed of three α4 and two β2 subunits (potentiating Zn2+, CMPI 
and NS9283 binding sites) (10, 14, 17), has 
revealed the critical role of this subunit in 
sensitivity to PAMs. Despite this insight, there is 
litle understanding of how PAM binding to sites 
in the α4 subunit is transduced into receptor 
potentiation. Alosteric modulators are thought 
to induce the same global conformational 
transitions that promote channel opening by 
agonists by affecting gating elements nearby 
their binding sites (18). In this respect, it is 
significant that the β1-β2 loop and Cys loop in 
the α4 subunit have been identified as 
components of the transduction pathway linked 
to potentiation of α4β2 nAChRs by the NS206 
binding site in the TMD (17). Additionaly, 
W621, the first residue in the N-terminal side of 
the post-M4 region of the α4 subunit, has been 
shown to afect βEST potentiating efficacy in a 
manner consistent with a role in transduction 
(19). 
 A suitable model system to examine the 
role of post-M4 and ECD agonist-binding-gating 
coupling elements in positive alostery of α4β2 
nAChRs is that involving potentiation of this 
receptor type through PAM sites located in the 
α4 subunit. An example of this type of α4β2 
nAChR PAM is βEST, whose binding site is in 
the post-M4 region of the α4 subunit (11). To 
identify additional alosteric modulator binding 
sites on the α4 subunit, we performed docking of 
nicotinic PAMs on a homology model of the 
α4β2 nAChR. These studies highlighted dFBr as 
a PAM that may bind the upper part of the TMD 
of the α4 subunit. By using mutagenesis 
together with the substituted cysteine 
accessibility method (SCAM), we confirmed 
that the upper half of a cavity between M3 and 
M4 hosts a potentiating dFBr site. Here, we 
demonstrate that alosteric signals from the dFBr 
and βEST potentiating binding sites are 
propagated to the Cys loop through interactions 
between F170 of the canonical FPF motif of the 
Cys loop and the final residue of the post-M4 
region. We also found that interactions between 
F167 in the Cys loop and Y309 in M3 are also 
important for the transduction of dFBr binding 
into potentiation of the α4β2 nAChR. 
 
RESULTS 
 The TMD of the α4 nAChR subunit 
houses a potentiating dFBr binding site. We 
examined the role of post-M4 and agonist 
binding-gating coupling elements in the α4 
subunit in the propagation of alosteric signals 
generated by binding of the PAM compounds 
βEST and dFBr to α4β2 nAChRs. The 
potentiating eficacy of βEST and dFBr is 
greater at α4β2 nAChRs containing three copies 
of α4 subunit (Figure 1), suggesting α4 encodes 
the binding and transduction elements for βEST 
and dFBr potentiation. The α4β2 nAChR can 
assemble in two functional stoichiometries, one 
with three copies of α4 and two copies of β2 
[(α4β2)2α4] and the other with two copies of α4 and three copies of β2 [(α4β2)2β2] (20). The 
alternate receptors difer in pharmacological 
properties, including sensitivity to agonists and 
alosteric modulators (20, 21).  
Previous studies have shown that βEST 
binds the post-M4 region of the α4 subunit (11). 
The site for dFBr binding has not been identified 
so far, although it has been suggested to lie 
within the ECD (22). Hence, to aid the 
identification of the potentiating dFBr binding 
site in the α4β2 nAChR, we performed docking 
stimulations with dFBr on a homology model of 
the α4β2 nAChR. Some docking positions were 
found in the pore, but the majority were found in 
the cavity between M3 and M4 of both the α4 
subunit (Figure 2A) and the β2 subunit (not 
shown). The position of dFBr in the later tended 
to be located more superficialy to the cavity. 
The M3-M4 cavity is a common alosteric site in 
pLGICs and is the target of a wide variety of 
alosteric modulators such as general 
anaesthetics in anionic pLGICs (23-25), 
neurosteroids in GABAA receptors (26) and 
PNU-120596 and LY-2087101 in α7 nAChRs 
(27).  
 Note that during revision of this 
manuscript the X-ray structure of the (α4β2)2β2 nAChR in a presumed desensitised conformation 
was published (28). We overlaid our homology 
model and the X-ray structure of the (α4β2)2β2 
receptors. This showed that the proposed dFBr 
binding region is fairly similar in both the 
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homology model and the X-ray structure of the 
(α4β2)2β2 receptor (Figure 2B) and 
demonstrates that our homology model is a valid 
tool to predict interactions between the α4β2 
nAChR and ligands. 
  To elucidate which residues in the TMD 
of the α4 subunit might contribute to the putative 
dFBr binding site, we prioritized residues with 
their side chain pointing towards the cavity and 
individualy substituted them with alanine. 
These studies highlighted α4 M3 Y309, F312, 
T313 and F316 and M4 L617 and F606 as 
residues that may interact with dFBr in the 
putative dFBr binding site to enhance, 
alostericaly, the ACh responses of α4β2 
nAChRs (Figure 2A, B). 
The consequences of the alanine 
substitutions on dFBr potentiation were assessed 
on α4β2 nAChRs assembled from equal ratios of 
α4 and β2 cDNA. This was necessary to obviate 
potential problems in data analysis due to low 
levels of functional expression, which may occur 
when working with mutants of homogeneous 
populations of α4β2 nAChRs. The receptors 
obtained using equal ratios of cDNA consist of 
approximately 80-90% of (α4β2)2α4 and 10-20% 
of (α4β2)2β2 receptors (20). Functional assays revealed Y309, F312 
and L617 as pivotal determinants of dFBr 
potentiation. Y309A and F312A abolished dFBr 
potentiation and increased dFBr EC50, compared 
to wild type (Figures 2C; Table 1). L617A 
reduced the maximal potentiating efect of dFBr 
(dFBr eficacy) by 9.5-fold and dFBr EC50 by 7-
fold (p < 0.001; n = 5), as compared to wild type 
(Figures 2C; Table 1). Increased polarity in 
these positions significantly afected dFBr 
potentiation. Thus, L617C decreased both dFBr 
eficacy (3.5-fold) and dFBr EC50 (6.7-fold) 
whereas F312C and Y309C obliterated the 
potentiating efects of dFBr (Table 1). To 
determine whether aromaticity at these positions 
is essential for dFBr potentiation, the efects of 
F312Y, Y309F and L617F on dFBr potentiation 
were examined. F312Y, Y309F and L617F 
reduced dFBr eficacy to similar levels. 
However, although L617F decreased dFBr EC50, F312Y and Y309F increased it, compared to 
wild type (Table 1). None of the Y309, F312 and 
F167 mutants afected ACh EC50 (Table 1). Alanine or cysteine substitutions on T313, F316 
or F606, which are predicted to lie below F312, 
also decreased dFBr eficacy and increased dFBr 
EC50 values, although their efects were less 
pronounced than those of Y309, F312 or L617 
(Table 1). Substitutions on T313 did not afect 
sensitivity to activation by ACh (Table 1), but 
al substitutions engineered on F316 and F606 
did (Table 1), suggesting that the efects of 
mutations on F316 and F606 on dFBr 
potentiation were a consequence of mutant-
induced perturbation of receptor function. 
To further confirm the role of the α4 
subunit on dFBr potentiation of α4β2 nAChRs, 
and further establish that M3 encodes binding 
residues for dFBr, we introduced α4F312A 
sequentialy into concatenated (α4β2)2α4 and 
(α4β2)2β2 receptors. Concatenated receptors have fixed stoichiometry and subunit 
arrangement, and these constructs have been 
shown to replicate the functional properties of 
the receptors assembled from loose α4 and β2 
subunits (21).  
As expected, introducing α4F312A in 
the α4 subunit contributing the principal 
component of the agonist site on the α4/α4 
subunit interface of the (α4β2)2α4 receptor (29, 30) reduced the potentiating eficacy of dFBr to 
(α4β2)2β2-like levels (Figure 2D), and dFBr 
potency decreased from 1.8 ± 0.5 µM to 2.5 ± 
0.1 µM (p < 0.05; n = 5), which is not diferent 
from the potency of dFBr on concatenated 
(α4β2)2β2 receptors. The additional agonist site on the (α4β2)2α4 receptor receptors plays a 
dominant role in determining the signature 
properties of this receptor type, as compared to 
the (α4β2)2β2 receptor (29–31). When the additional agonist site is ablated, (α4β2)2α4 receptor displays (α4β2)2β2-like pharmacology 
(30, 31), including sensitivity to agonists and 
alosteric modulators (11, 20, 21). Significantly, 
introducing α4F312A in one of the two agonist 
sites of the (α4β2)2β2 receptor reduced dFBr 
eficacy by approximately 50% (Figure 2D) and 
decreased dFBr potency to 12 ± 1 µM (p < 
0.001; n =5). When the mutation was introduced 
in al copies of α4 in both receptor types, the 
receptors were no longer sensitive to 
potentiation by dFBr (Figure 2D). These 
findings indicate that pivotal determinants of 
dFBr potentiating potency and eficacy are 
encoded by the α4 subunit. 
Efects of dFBr on MTSET reaction 
rates. Demonstrating that dFBr can access 
residues in the top half of the cavity between M3 
and M4 of the α4 subunit would further support 
the conclusion that this region houses a dFBr 
potentiation site. We determined this by 
assessing the ability of dFBr to protect L617C 
from covalent modification by the thiol 
 Transduction pathways in α4β2 nicotinic receptor potentiation 
 
4 
 
compound MTSET (protection assays). L617C 
decreased the eficacy of dFBr but had no efects 
on ACh EC50, indicating that the observed changes in dFBr potentiation are not linked to 
changes in ACh EC50 (Table 1). Neither F312C nor Y309C were used for dFBr protection assays 
because these mutants abolished dFBr 
potentiation (Table 1). We first determined the 
accessibility of L617C to covalent modification 
by MTSET by exposing α4L617Cβ2 receptors to 
MTSET for 2 min folowing stabilisation of ACh 
EC10 responses. ACh-elicited responses and 
dFBr potentiation of ACh responses were 
measured before and after MTSET exposure 
(Figure 3A). MTSET had no efect on the ACh responses or dFBr potentiation (Figure 3B) of 
wild type receptors, indicating that any change 
measured in ACh responses or dFBr potentiation 
after MTSET exposure is due to MTSET-
modification of L617C. Potentiation of ACh 
responses was abolished by MTSET, indicating 
that α4L617C is fuly accessible to MTSET 
(Figures 3A, B). This efect is selective because 
MTSET treatment of α4F316C, which we 
propose perturbs dFBr potentiation of α4β2 
receptors indirectly, reduced dFBr potentiation 
by only 30% (Figure 3B), indicative of limited 
accessibility to MTSET at this position. For the 
protection assays, we first stabilised the currents 
elicited by an EC10 concentration of ACh at 
α4L617Cβ2 receptors and then co-applied ACh 
EC10 with EC100 dFBr to test the maximal dFBr potentiation on α4L617Cβ2 receptors. Next, a 
sequence of applications (10 seconds) of 20 µM 
MTSET in the presence or absence of dFBr 
EC100 (10 µM) was tested for a total time of 40 
seconds (Figure 3C). After each application 
ACh EC10 + dFBr EC100 responses were tested for changes in the amplitude of the responses 
(Figure 3C). The reaction rate of MTSET with 
α4L617C in the absence of dFBr was 12-fold 
faster (k1 0.05 ± 0.01 s-1) than in the presence of dFBr (k1 0.004 ± 0.0 03 s-1) (p < 0.0001; n = 4) 
(Figure 3D). Together, the findings show that 
dFBr protects L617C from reacting with 
MTSET, which would occur if dFBr binds the 
dFBr binding site in the top-half cavity between 
M3 and M4 in the α4 subunit. 
 Y309 and F312 are conserved in the β2 
subunit (Figure 4A), and docking studies 
indicate that dFBr may bind in a narow cavity 
between the top of M3 and M4 in β2 (not 
shown). We therefore tested whether Y300 and 
F303 in the β2 subunit, equivalents to α4Y309 
and α4F312, respectively, altered the 
potentiating efects of dFBr on α4β2 receptors. 
Incorporation of β2F303A or β2Y300A 
decreased both dFBr eficacy and potency 
(Table 1). However, because β2Y300A and 
β2F303A markedly decreased ACh EC50 (p < 0.0001; n = 5), their efects on dFBr eficacy 
likely reflect perturbations to receptor function 
rather than direct efects on dFBr potentiation. 
The TMD of pLGICs play a pivotal role in 
gating, and structural integrity in some regions is 
criticaly important for this function (32-34). 
Finaly, it has been previously suggested 
that the potentiating binding site of dFBr is 
located in the β2+/α4- interface of the α4β2 
nAChR and that key contributors to this site are 
β2 subunit residues W176, Y120, D217 and 
D218 (22). We performed alanine substitutions 
on these residues but found that none disturbed 
dFBr potentiation significantly (Table 2). 
The Cys loop afects dFBr potentiation. 
Surprisingly, F312, Y309 and L617 are 
conserved in the α3 nAChR subunit (Figure 
4A), yet α3β2 nAChRs were found to be only 
inhibited by dFBr (IC50 118 ±5 µM; n = 6) 
(Figure 4B). Inhibition of α3β2 nAChRs by 
dFBr is not mediated by a site in the M3-M4 
cavity because alanine substitution on α3F310, 
the α3 residue equivalent to the crucial F312 in 
the α4 subunit, has no efect on dFBr-mediated 
inhibition (IC50 115 ±7 µM; n = 6) (Figure 4B). 
In addition, inhibition of α3β2 nAChRs is 
voltage-dependent (not shown) and the curent 
responses to ACh EC10 in the presence of concentrations of dFBr greater than 10 μM 
rebound, strongly suggestive of ion channel 
blockade (Figure 4B inset). Together, these 
findings suggest that the α3 subunit may lack 
structural elements required for transducing the 
positive alosteric signals generated by binding 
of dFBr to the M3-M4 cavity. The agonist 
binding-gating coupling elements, the β1-β2 
loop and the Cys loop, have been shown to 
contribute to the transduction of positive 
alosteric signals in α4β2 nAChRs (17). 
Importantly, α3 and α4 difer in five amino acid 
positions in these regions, two in loop β1-β2 and 
three in the Cys loop (Figure 4A). To determine 
whether these residue diferences are defining 
factors for sensitivity to potentiation by dFBr, 
we mutated the α4 residues to their α3 
counterparts. Neither mutating α4S162 in the 
Cys loop to lysine, its α3 equivalent, nor 
changing α4 loop β1-β2 into an α3 β1-β2 loop 
[α4(α3β1- β2 loop)] had any significant efect on 
dFBr potentiation (Figure 4C, Table 3). In 
 Transduction pathways in α4β2 nicotinic receptor potentiation 
 
5 
 
contrast, substituting F167 in the α4 subunit Cys 
loop with its α3 equivalent (a tyrosine) reduced 
the eficacy of dFBr by five-fold without 
changes in dFBr EC50 (Figure 4C; Table 3). In 
addition, alanine substitution of F167 had no 
efect on dFBr EC50 but almost abolished potentiation by decreasing dFBr eficacy by 9.6 
fold (Figure 4C; Table 3). 
 F167 is next to the canonical FPF motif 
caried by the Cys loop in pLGICs, which 
interacts with neighbouring pre-M1 in the ECD 
and the M2-M3 linker in a wel-established 
pathway linking agonist binding to channel 
gating (5, 6). We examined the relevance of FPF 
for dFBr potentiation by individual mutations on 
the α4 Cys loop motif (F168, P169, F170). 
Substitutions on proline (P169A, P169F, P169L) 
did not yield functional expression. Alanine 
substitution on F170 was wel tolerated and 
decreased dFBr potentiation eficacy by 5.9 fold 
(Figure 4C; Table 3). Alanine substitution on 
F168 did not yield functional expression (not 
shown), and F168L, which did not afect the 
functional expression of α4β2 nAChRs, had no 
efect on dFBr potentiation (Figure 4C; Table 
3). 
 The discovery that F167 and F170 are 
capable of influencing dFBr potentiation of α4β2 
nAChRs suggest that the Cys loop may be part 
of the transduction mechanism for potentiation 
by dFBr. Interactions between the Cys loop and 
post-M4 are thought to be important for eficient 
gating of muscle nAChRs (8). To determine the 
relevance of α4 post-M4 (Figure 4A) for dFBr 
potentiation of α4β2 nAChRs, we first 
determined the efect of dFBr on receptors 
containing α4 subunits devoid of post-M4 (α4-
PM4). In accord with previous studies (35), we 
found that α4-PM4β2 nAChRs were functional, 
albeit with reduced sensitivity to ACh, in 
comparison to wild type (Table 3). Significantly, 
removal of post-M4 reduced dFBr eficacy by 
8.8-fold (Figure 5A; Table 3). To confirm the 
importance of post M4 for dFBr potentiation, we 
examined dFBr efects on α4LMAREDAβ2 
nAChRs. α4LMAREDA comprises the ECD and 
TMD from the α4 subunit linked to α3 post-M4 
(LMAREDA) (Figure 4A). If post-M4 in the α4 
subunit is a key determinant of dFBr 
potentiation, α4LMAREDAβ2 nAChRs should 
not be potentiated by dFBr. As shown in Figure 
5A (Table 3), dFBr potentiation was ablated in 
α4LMAREDAβ2 nAChRs. To elucidate which 
α4 post-M4 amino acid residues (WLAGMI) are 
important for dFBr potentiation of α4β2 
nAChRs, we examined the efects of dFBr on 
alanine mutants of the α4 post-M4 region. 
Individual alanine substitutions on the sequence 
WLAGM reduced potentiation but not 
significantly (Figure 5A; Table 3). In contrast, 
alanine substitution of the final residue of α4 
subunit post-M4 (I626) abolished dFBr 
potentiation (Figure 5A; Table 3). 
 α4 M4 caries a double proline motif 
(PP) that precedes post-M4 (Figure 4A) that is 
conserved only in the α4 and α2 nAChR 
subunits, both of which are sensitive to dFBr 
potentiation (11, 36). The PP motif may 
introduce considerable restrictions on the 
orientation and mobility of post-M4, which 
could be pivotal for dFBr potentiation. To 
determine the relevance of the PP motif for dFBr 
potentiation, the prolines were mutated to 
alanine individualy as wel as simultaneously. 
As shown in Figure 5A (Table 3), AAWLAGMI 
obliterated the potentiating efects of dFBr and 
APWLAGMI or PAWLAGMI reduced 
potentiation by 9-fold. Furthermore, exchange of 
the PP motif for QP, the motif preceding post-
M4 in the α3 subunit (Figure 4A), decreased 
dFBr potentiation by 8.2-fold (Figure 5A; Table 
3). 
To further confirm the relevance of post-
M4 and the double PP motif for dFBr 
potentiation, we tested the efect of changing the 
α3 subunit QPLMAREDA region to the 
equivalent α4 region (PPWLAGMI). We had 
shown in this study that α3β2 nAChRs are 
inhibited by dFBr (Figure 4B), even though 
residues pivotal for potentiating dFBr binding in 
the α4 subunit are conserved in the α3 subunit 
(Figure 4A). If dFBr potentiation requires the 
binding site in the top-half of the cavity between 
M3 and M4 and the PPWLAGMI sequence, 
α3PPWLAGMIβ2 receptors should be sensitive 
to potentiation by dFBr. As shown in Figure 5B-
C, α3PPWLAGMIβ2 nAChRs were potentiated 
by dFBr (Imax = 4 ± 0.2; EC50 7 ±0.2 µM; n = 5), 
unlike wild type α3β2 nAChRs. Significantly, 
incorporation of F310A into α3PPWLAGMI 
abolished dFBr potentiation (Imax 0.99 ±0.06; n = 
4; p < 0.001) (Figure 5C). 
 Interactions between post-M4 and Cys 
loop are necessary for dFBr potentiation. The 
atomic structure of post-M4 in pLGICs has not 
been resolved (e.g., 3, 4, 29). However, since it 
has been proposed that post-M4 in muscle 
nAChRs may interact with the Cys loop to 
modulate gating (8),we hypothesised that post-
M4 extends towards the Cys loop and that 
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binding of dFBr to the M3-M4 cavity promotes 
interactions between F170 and I626 (Figure 
6A), leading to potentiation of receptor function. 
To test this possibility, we disrupted any 
possible functional interdependence by mutating 
the residues individualy (F170I, I626F) and also 
in pairs (F170I-I626F) to potentialy restore 
functional interdependence. Mutants F170I, 
I626F and F170I-I626F were wel tolerated, al 
yielding functional expression. F170I and I626F 
reduced dFBr potentiation by 4.6-fold and 4.8-
fold, respectively, as compared to wild type 
(Figure 6B, E; Table 3). When both mutations 
were present (F170I-I626F), dFBr potentiation 
was increased by 2.4-fold, in comparison to the 
single mutants (Figure 6B; Table 3). Moreover, 
dFBr eficacy was 1.2-fold higher than the sum 
of the dFBr eficacy at the individual mutants (p 
< 0.01, n = 4). If mutants F170I and I626F acted 
independently, the efect of the double mutation 
should be additive. We also examined whether 
the double proline could interact with F170 but 
mutants F170P, F170P-P620F and F170P-P626F 
did not yield functional expression.  
 We next examined the possible role of 
F167 in dFBr potentiation. F167 is close to L305 
in the M2-M3 linker of the α4 subunit (Figure 
6A), a residue that in the muscle nAChR is 
energeticaly coupled to the Cys loop and pre-
M1 region to contribute to gating (6). α4F167L 
had no efect on dFBr potentiation, whereas 
L305F abolished it (Figure 6C; Table 3). When 
both mutations were present, dFBr potentiation 
was abolished (Figure 6C; Table 3), indicating 
that the efect of L305 on dFBr potentiation is 
not dependent on F167. The side chain of F167 
is also predicted to orientate towards Y309 in 
M3 (Figure 6A). We established earlier that 
Y309 (Figure 2B) and F167 (Figure 4C) are 
criticaly important for dFBr potentiation. To 
determine whether F167 and Y309 contribute to 
dFBr potentiation interdependently, we mutated 
F167 to tyrosine and Y309 to phenylalanine, and 
examined the effects of these mutants on dFBr 
potentiation individualy or in pair. F167Y and 
Y309F decreased dFBr efficacy by 4.8- and 3.8-
fold, respectively, compared to wild type 
(Figure 6D, E; Table 3). When the mutations 
were introduced simultaneously (F167Y-
Y309F), dFBr eficacy was restored to near wild 
type values (Figure 6D, E; Table 3). 
 F170 and I626 interactions are 
necessary for βEST potentiation. βEST is an 
established positive alosteric modulator of α4β2 
nAChRs (11, 19, 35). Previous studies have 
shown that residues in α4 post-M4 are involved 
in both binding (AGMI, the last four residues of 
post-M4) and transduction (W621, the first post-
M4 residue) of potentiating βEST (11, 35). As 
for dFBr potentiation, the potentiating eficacy 
of βEST is greater at (α4β2)2α4 receptors 
(Figure 1A). To assess whether the Cys loop - 
post-M4 interactions that afect dFBr 
potentiation are relevant for βEST potentiation, 
we assessed the efects of F170I and I626F on 
βEST potentiation, individualy and in pairs. 
Individualy, F170I and I626F abolished βEST 
potentiation (Figure 7A; Table 4). When both 
mutations were present (F170I-I626F), βEST 
efficacy was restored to near wild type values 
(Figure 7A, Table 4). 
 We also examined whether F167 and 
Y309 were relevant for βEST potentiation. 
Mutants F167Y, Y309F or F167Y-Y309F had no 
impact on βEST potentiation (Figure 7B). These 
results suggested that F167 and Y309 may afect 
selectively potentiation by compounds that bind 
the M3-M4 cavity. To examine this possibility, 
we assayed the efect of F167A, Y309A and 
F3212A on βEST potentiation. βEST 
potentiation was not afected by F167A, Y309A 
or F312A (Table 4). In contrast, alanine 
substitution on L617 abolished βEST 
potentiation (Table 4). 
 
DISCUSSION 
This study provides the first 
demonstration that interactions between the Cys 
loop and the post-M4 region of the α4 subunit 
afect potentiation of α4β2 nAChR function by 
PAMs that bind the TMD region of the α4 
subunit. Our data reveal that in the α4 subunit 
F170 of the Cys loop and I626, the final residue 
of post-M4, are functionaly coupled, and show 
that this coupling is essential to transduce 
binding of βEST and dFBr into potentiation of 
α4β2 nAChR function. This conclusion is based 
on the observation that individual residue swaps, 
F170I and I626F, ablated (βEST) or atenuated 
(dFBr) potentiation, whereas double mutant 
(F170I-I626F) restored potentiation to wild type 
values (βEST) or increased it above the levels 
expected from simple additivity (dFBr). In 
addition, individual alanine mutations on F170 
and I626 also afected βEST and dFBr 
potentiation, in a manner consistent with 
annulment of the functional link between them. 
Significantly, transfer of the α4 subunit post-M4 
region to the α3 subunit, which conserves the 
key dFBr binding residues in the TMD, 
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conferred sensitivity to dFBr potentiation to 
α3β2 nAChRs. A similar phenomenon has been 
reported for the potentiation of α4β2 nAChR by 
βEST (35).  
Without structural data for α4 post-M4, 
it is not possible to infer any specific details 
about the structural framework that could 
account for F170/I626 functional 
interdependence and its role in dFBr and βEST 
potentiation. In the muscle nAChR structure, 
post-M4 extends beyond the lipid bilayer 
towards the Cys loop to seemingly interact with 
F137 (F170 in α4) (8). Moreover, the post-M4 
residue that appears to interact with F137 is 
Q435, a residue that aligns with α4I626 (Figure 
4A). The functional consequences of putative 
F137/Q435 interactions have not been examined 
so far, but it has been suggested that they may 
contribute to coupling agonist binding to channel 
gating, as wel as transducing the alosteric 
efects of lipid binding to M4 (8). In regard of 
the α4β2 nAChR, localised motion transitions 
triggered by binding of PAMs to the TMD could 
promote F170-I626 gating interactions, leading 
to more eficacious agonist-triggered receptor 
activation. Given that M4 is covalently linked to 
post-M4, local structural changes induced by 
PAM binding to the M3-M4 cavity could be 
relayed to post-M4 through M4 motions. In 
accord with this possibility, we found dFBr and 
βEST may engage in binding interactions with 
M4 L617, and these binding interactions are 
likely to trigger M4 motions that could 
subsequently alter the orientation of post-M4. 
Significantly, NMR structures of the TMD of the 
α4β2 nAChR bound to alosteric inhibitors 
halothane or ketamine show that binding of these 
modulators to their binding sites in the TMD 
elicits changes in protein dynamics beyond the 
binding sites (37). Also, molecular dynamics 
simulations show the M4 as a structuraly 
dynamic element undertaking substantial motion 
during muscle nAChR gating (38). Additionaly, 
M4 is known to afect gating of the muscle 
nAChR (32) and, more recently, it has been 
proposed that enhanced interactions between M4 
and M1-M3 promotes channel function in GLIC, 
a prokaryotic pLGIC (7).  
 Extensive mutagenesis studies of α4 
post-M4 have led to the view that the final four 
residues of the α4 subunit bind βEST and that 
the C-terminus of the tail likely plays a role in 
transduction (35). In contrast, our data strongly 
suggests that the last residue of post-M4 (I626) 
functionaly couples to F170 to transduce 
binding of βEST into receptor potentiation. 
Without structural data for post-M4 of the α4β2 
receptor or adequate probes to photo-label the 
binding site for βEST, we cannot easily 
reconcile our findings with the view that βEST 
binds the tail of post-M4. However, our 
observation that substitutions of M4 L617 
ablated βEST potentiation, suggests L617 may 
contribute to the βEST binding site, locating this 
site to the top part of M4. This would be in 
accord with the observation that neither F167 
nor Y309 had any efects on βEST potentiation. 
Moreover, a binding site on the top of M4 would 
place the site nearby to F170 and I626, the 
crucial transduction components for this site.  
An important finding of this study is that 
a cavity between the top half of the M3 and M4 
of the α4 nAChR subunit hosts the potentiating 
binding site of dFBr. M3 (F312 and T313) and 
M4 (L617) residue side chains are predicted to 
project towards the M3-M4 cavity and reside 
suficiently close to one another to al be able to 
bind dFBr. When their capacity to bind dFBr 
was annuled by alanine substitution, the 
sensitivity to dFBr potentiation was either 
abolished (as for F312A) or drasticaly reduced 
(as for L617A or T313). Moreover, protection 
assays with MTSET demonstrated that dFBr 
impeded accessibility of L617C by MTSET, 
suggesting that dFBr occupies the cavity towards 
which the side chain of residues L617, F312 and 
T313 orientates. This cavity is a common 
alosteric site in pLGICs and is the target of a 
wide variety of alosteric modulators such as 
general anaesthetics in anionic pLGICs (23-25), 
smal neurosteroids in GABAA receptors (26) 
and PNU-120596 and LY-2087101 in α7 
nAChRs (27). Alanine or cysteine substitutions 
on M3 F316 or M4 F606 also atenuated dFBr 
potentiation but their efects on ACh EC50 suggest these residues may afect dFBr 
potentiation indirectly by afecting channel 
gating. In support of this possibility, it has been 
reported that F316, a residue highly conserved in 
the α subunits of the nAChR family, afects 
gating in the muscle nAChR (33, 34) and M4 is 
wel-established gating modulator domain (8, 
34).  
 In addition to F170 and I626, which we 
suggest to be transducing elements linked to the 
binding sites of βEST and dFBr, F167 and Y309 
were also identified as important components of 
the transduction of dFBr binding. Individualy, 
mutants F167Y and Y309F drasticaly atenuated 
dFBr potentiation but the double mutant F167Y-
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Y309F restored potentiation to wild type levels. 
Furthermore, individual alanine substitutions on 
these residues afected dFBr potentiation 
similarly, supporting the possibility of these two 
residues being involved functionaly. 
Importantly, F167 is predicted to project 
downwards towards M3 to meet the side chain 
of Y309 that extends upwards, thus positioning 
the transduction complex nearby the dFBr site. 
Furthermore, F167 precedes the critical FPF 
gating motif. Thus, conceivably, F167-Y309 
interactions could optimise the gating 
conformations of the Cys loop FPF motif, 
leading to enhanced receptor function.  
 As Y309 is not predicted to project 
towards F170, F167-Y309 interactions are 
unlikely to be part of the F170-I626 transducing 
pathway. Thus, analogously to the gating of the 
muscle nAChR, in which the β1-β2 and Cys 
loops appear to act jointly on the M2-M3 linker 
to gate the ion channel (6), dFBr binding is 
transduced by two independent pathways that act 
on the Cys loop to produce receptor potentiation. 
Compared to βEST, dFBr is approximately 7-
fold more eficacious, thus suggesting that a 
functional consequence of F167-Y309 and F170-
I626 dFBr-dependent interactions is greater 
potentiating eficacy. 
 Finaly, given that the FPF motif of the 
Cys loop and M3 are highly conserved in the 
nAChR subunits that form heteromeric nAChRs 
(Figure 4A), the structural element that is 
pivotal in determining sensitivity to potentiation 
by dFBr and βEST is post-M4. In comparison to 
other α subunits that form heteromeric receptors 
insensitive to dFBr potentiation (e.g., muscle 
nAChR, α3β2 nAChR), post-M4 in α4 is more 
hydrophobic, suggesting that it could extend 
more easily towards the hydrophobic ECD/TMD 
coupling region than less hydrophobic M4 tails. 
Furthermore, the presence of the signature 
double proline motif preceding α4 post-M4 
likely places considerable constraint on the 
orientation of post-M4, perhaps anchoring post-
M4 to the membrane underneath the Cys loop 
FPF motif, thereby aiding interactions of this 
domain with the F170 in the Cys loop. In accord 
with this view, double or individual alanine 
substitutions on PP severely atenuated (AP or 
PA) or ablated (AA) dFBr potentiation. 
 The transduction mechanism presented 
here for PAM binding sites in the TMD of the 
α4β2 nAChR provides strong experimental 
evidence that interactions between the TMD and 
the Cys loop are critical for alosteric modulation 
of pLGICs by PAMs. Thus, in addition to its role 
in coupling agonist-binding to channel gating, 
the Cys loop also couples TMD to the channel 
gate. The Cys loop is thus a hub that conveys 
gating signals to the channel gates from both the 
ECD and the TMD.  
 
EXPERIMENTAL PROCEDURES  
Materials. DFBr was purchased from 
Tocris Chemicals (UK) and βEST from Sigma-
Aldrich, UK. The cationic methanethiolsulfonate 
reagent [2-(Trimethylammonium) ethyl] 
methanethiosulfonate (MTSET) was purchased 
from Toronto Chemicals (Canada). 100 mM 
stocks were prepared and stored at -80 C°. Just 
before use, MTSET stocks were diluted to the 
appropriate concentration in Ringer’s solution 
and were applied immediately to the oocytes. 
Xenopus laevis (X. laevis) were purchased from 
Portsmouth University (Portsmouth, UK) or 
Xenopus-One (Chicago, USA). Ovaries were 
dissected from the toads using procedures in 
accordance with the UK Home Ofice 
regulations. 
Molecular Biology. Human cDNA of the 
α4 and β2 subunits were cloned into the 
expression vector pCI (Promega), whilst the α3 
nAChR subunit cDNA (kindly provided by Prof 
L Siviloti from UCL, London, UK) was cloned 
into pcDNA3.1 (Invitrogen). Site directed 
mutagenesis was performed using the 
QuikChange mutagenesis kit (Stratagene, 
Europe). The ful-length sequence of mutant 
subunit cDNAs was verified by DNA 
sequencing (BioSource Sequencing, Oxford and 
Eurofins-MWG, Germany). We present the 
numbering of the residues in terms of the ful 
length, including the signal sequence. To obtain 
the position in the mature form, subtract 28 from 
the number for α4, 25 for 2 and 31 for α3. 
 Expression of nAChR in Xenopus 
Oocytes. Stage V and VI Xenopus oocytes were 
prepared as previously described (10). Wild type 
or mutant human α4 or α3 subunit cDNAs were 
co-injected with β2 subunit cDNA into the 
nuclei of oocytes in a volume of 18.4 nl/oocyte 
at equal ratios, using a Nanoject Automatic 
Oocyte Injector (Drummond, Broomal, PA, 
USA). The total amount of cDNA injected per 
oocyte was kept constant at 2 ng. After injection, 
oocytes were incubated at 18 °C for 2-5 days in 
a modified Barth’s solution containing 88 mM 
NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM 
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 15 mM HEPES and 5 mg/l neomycin (pH 7.6). 
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Equal ratios of α4 and β2 subunits yields a 
mixture of two functional stoichiometries, 
(α4β2)2α4 and (α4β2)2β2. These two receptor types have distinct pharmacological properties, 
including sensitivity to activation by ACh (20). 
To test the efects of dFBr in the alternate α4β2 
receptors, we expressed fuly concatenated 
receptors. We have shown previously that 
concatenated α4β2 receptors replicate the 
properties of their non-linked counterparts (21). 
Concatenated receptors were constructed as 
α4β2 receptors as previously described (21). To 
introduce mutations into the subunits of the 
concatemers, the mutations were first introduced 
in free subunits cloned into a modified pCI 
plasmid (Promega, UK) and, folowing sequence 
verification by double stranded DNA sequencing 
(SourceBioscience, Oxford, U. K), the subunits 
were ligated to the desired position in the 
concatemer using unique enzyme restriction sites 
(21). To verify that the mutated subunits were 
incorporated into the concatenated receptors, 
folowing ligation and DNA amplification, the 
mutated subunit were excised enzymaticaly 
from the concatemer for sequence verification 
by double stranded DNA sequencing 
(SourceBioscience, Oxford, U. K). 
Electrophysiology and Concentration Response 
Curves. Recordings were performed 2 - 5 days 
post-injection, as previously described (10). 
Briefly, oocytes were placed in a 0.1 ml 
recording chamber and perfused with modified 
Ringer’s solution (in mM: NaCl 150, KCl 2.8, 
HEPES 10, CaCl2 1.8; pH 7.2, adjusted with 
NaOH) at a rate of 15 ml/min. Note that it has 
been reported that (α4β2)2β2 nAChRs are 
potentiated by HEPES, possibly by binding a 
site in the signature β2/β2 interface of this 
receptor type (39). We have tested the efects of 
HEPES on the function of (α4β2)2β2 nAChRs 
and found no efects. Moreover, we compared 
the sensitivity of (α4β2)2β2 and (α4β2)2α4 nAChRs to ACh, Zn2+, dFBr and βEST using 
Ringer solutions bufered by HEPES or 
phosphate bufer and found no diferences (not 
shown). In accord with these findings, the 
recently published X-ray structure of the 
(α4β2)2β2 nAChRs suggests ligands may not 
access the β2/β2 interface easily (28). Current 
responses were obtained by two-electrode 
voltage-clamp recording at a holding potential of 
-60 mV using an Oocyte Clamp OC-725C 
amplifier (Warner Instruments, USA) and 
Labscribe software (Iworx, NH, USA). 
Electrodes contained 3 M KCl and had a 
resistance of < 1 MΩ. ACh, dFBr and βEST 
were prepared daily in Ringer’s solution from 
frozen stocks (10 mM). Al experiments were 
carried out at room temperature. For wild type 
and mutant α4β2 or α3β2 nAChR, a 6 to 7 point 
concentration-response curve was generated for 
ACh alone or with alosteric modulators (dFBr 
or βEST). Peak currents for ACh were 
normalised to the currents elicited by 1 mM 
(ACh EC100). Alosteric modulators were co-applied with ACh EC10 for the receptor under study and the peak curent responses were 
normalised to the responses elicited by ACh 
EC10 alone. Oocytes were superfused with 
Ringer’s solution for 5 min between al drug 
applications. To eliminate data interpretation or 
analysis arising from run-up or run-down of 
current responses over the course of 
experiments, al oocytes were initialy stabilised 
with ACh EC100. Oocytes were discarded if the response to ACh EC100 varied by more than ± 
10%. 
 Substituted Cysteine Accessibility 
Method. Accessibility of introduced cysteines to 
MTSET was determined by exposing the 
cysteines to a maximal concentration of MTSET 
(1 mM) (40). Briefly, oocytes were stabilized 
before addition of MTSET by application of 
ACh and ACh + dFBr at 5-min intervals until the 
ACh-activated curents (IACh) and dFBr 
potentiation of IACh varied by less than 6%. ACh 
concentrations used were EC10 and dFBr concentration used was EC100 for each mutant. After the ACh and dFBr responses were 
stabilized, freshly diluted 1 mM MTSET was 
applied for 2 min, the cel was washed for 5 min, 
and then ACh and ACh + dFBr responses were 
measured. The efect of MTSET on dFBr 
potentiation of ACh responses was calculated 
as % Change = [(Iafter/Iinitial) – 1) x 100], where Iinitial is the response to ACh EC10 + dFBr EC100 
prior to MTSET application and Iafter is the 
response to ACh EC10 + dFBr EC100 after 
MTSET application. After MTSET reactions, 
oocytes were exposed to the redox reagent 1, 4 
dithiothreitol (1 mM, 2 min) to confirm that any 
changes observed were the result of covalent 
modification of the substituted residues by 
MTSET.  
Rate of MTSET Modification. The rate 
of MTSET covalent modification of introduced 
cysteines was determined by measuring the 
efect of sequential applications of sub saturating 
MTSET (20 µM) on potentiation of EC10 ACh 
responses by EC100 dFBr. Folowing stabilisation 
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of dFBr potentiation of ACh responses, MTSET 
was applied for 5 s and the cel was then washed 
for 70 s and the procedure was repeated until 
changes in dFBr potentiation reached a plateau. 
Before the reaction rate was measured, ACh and 
ACh + dFBr were applied every 3.7 min until 
the response varied by less than 5%. The efects 
of dFBr on the rate of MTSET modification was 
tested by co-applying MTSET with EC100 dFBr. 
The change in current was ploted versus 
cumulative time of MTSET exposure. Peak 
values at each time point were normalized to the 
initial peak at time 0 s, and the data points were 
fit with a single-exponential decay function: y = 
span x e-kt + plateau (Graph Pad Software), 
where k is the first pseudo-first order rate 
constant of the reaction. Plateau is the peak ACh 
current at the end of the reaction and Span is 1 – 
plateau.  
Homology Modeling and Docking. Homology 
models of the α4β2 nAChRs were constructed 
using MODELLER 9.12 (41) and were based on 
the 5-HT3 receptor X-ray structure (PDB ID: 4PIR) at 3.5 Å resolution (42). The template X-
ray structure comprises the ECD, the TMD and 
part of the intracelular domain. Four residues 
are missing in the extracelular M2-M3 loop, and 
more than 60 residues are missing in the 
intracelular linker between M3 and M4. 
Sequences of the human α4 and β2 nAChR 
subunits were obtained from the ExPASy 
proteomics server with accession numbers 
P43681 (α4) and P17787 (β2) and aligned to the 
5-HT3R subunits using the alignment function of 
MODELLER (align2d) and, for comparison, 
also using two diferent alignment tools from the 
European Bioinformatics Institute (EBI), 
EMBOSS Stretcher and EMBOSS Needle, 
respectively. The sequence identity is 25% and 
the sequence similarity is approximately 45%. 
The three alignments were compared and the 
final alignment constructed with manual changes 
in regions where the alignment algorithms were 
not optimal. Disulphide bonds were included and 
50 models for each of (α4)3(β2)2 (α4-β2-α4-β2-
α4) and (α4)2(β2)3 (α4-β2-α4-β2-β2) were 
constructed. The models mainly varied in 
regions where the template was missing, and the 
best models were chosen based on analysing the 
MODELLER scores (molpdf, DOPE and 
GA341). The 3-4 best models in terms of al of 
these scores were further assessed with QMEAN 
(43) and the best QMEAN scoring model from 
this process was chosen as the appropriate model 
for docking. The template is missing for the C-
terminal four residues of post-M4, and there 
residues are therefore not included in any of the 
generated models.  
A 3D model of dFBr was constructed in 
Maestro version 9.7 (Schrödinger, LLC, New 
York, NY, 2012 (academic version) in both 
positively charged and neutral state. Protein and 
ligand models were prepared for docking using 
Autodock Tools (44) and docking calculations 
were performed with Autodock Vina (45). A 
large box of 74x74x40 Å3 centered in the 
extracelular half of the ion channel and covering 
a large part of the TMD of al five chains was 
used as the search space for docking 
calculations. 20 binding models were generated 
for each ligand docked into each protein model, 
i.e. 80 poses were generated in total. The binding 
models were analysed visualy as the docking 
scores were al very similar (best score among 
80 posed was -7.5 and the worst -6.2). 
Data Analysis. Concentration-response 
data analysis was performed using nonlinear 
regression analysis using Prism 5 software 
(Graph Pad, CA, USA). For simplicity ACh 
concentration-response curves were fit to a 
monophasic three-parameter Hil equation using 
GraphPad 5, although α4β2 nAChRs assembled 
from equal ratios of α4 and β2 cDNA yield 
biphasic ACh concentration-response curves 
(11). Concentration-response curves for the 
potentiating efects dFBr or βEST were also fit 
to the monophasic form of the Hil equation. Hil 
equation parameters, MTSET accessibility and 
MTSET rate constants were analysed by one-
way analysis of variance (ANOVA), folowed by 
a Dunnet post Hoc test. P values of < 0.05 were 
considered as significantly diferent
. 
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Non-standard abbreviations. 17β-Estradiol, βEST; desformylflustrabromine, dFBr; 
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channels, pLGICs; nicotinic acetylcholine receptor, nAChR; methanesulphonate reagent, 
MTS; [2-(Trimethylammonium) ethyl] methanethiosulfonate, MTSET; substituted cysteine 
accessibility method, SCAM; transmembrane domain, TMD 
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Table 1. Concentration effects of ACh and dFBr on wild type and mutant α4β2 nAChRs. 
The concentration efects of dFBr were determined on ACh responses elicited by EC10 ACh 
concentrations. The data points were used to generate concentration response curves from 
which EC50, Hil coeficient (nH) (not shown) were estimated, as described in Experimental Procedures. Maximal potentiation by dFBr of ACh EC10 current responses (Imax pot) was 
calculated as (IACh EC10 + dFBr) /IACh EC10.Values represent the mean ± SEM of n number of experiments. Asteriks indicate that the change in EC50 or Imax pot. is statisticaly significant (*, 
p < 0.05; **, p < 0.001, ***, p < 0.0001), as measured by one-way ANOVA with Dunnet’s 
correction. 
 
 
 
Α4 TMD 
 
Receptor 
ACh DFBr 
EC50 (µM) 
n EC50 (µM) 
Imax pot n 
α4β2 100± 7 20 1.33±0.03 10.6±2.0 15 
 
 
 
 
 
3 
α4Y309Aβ2 116±19 8 0.0±0*** 1.01±0.03*** 9 
α4Y309Cβ2 109±16 6 0.0±0*** 1.02±0.06*** 7 
α4Y309Fβ2 115±5 4 0.4±0.1* 2.75±0.3* 6 
α4F312Aβ2 102±6 15 0.0±0*** 1±0.001** 12 
α4F312Yβ2 113±16 8 0.26±0.09* 2.4±0.8* 6 
α4F312Cβ2 93±10 9 0.0±0*** 1.04±0.06** 8 
α4T313Aβ2 123±7 9 1.8±0.3* 2.2±0.4** 9 
α4T313Cβ2 131±15 4 1.98±0.3* 2.91±0.4** 4 
α4F316Aβ2 161±30* 8 2.22±0. 04** 3.9±0.3** 8 
α4F316Cβ2 124±1* 4 2.5±0.1* 4.2±0.4**3 4 
 
 
 
4 
α4L617Aβ2 118±18 4 11±3* 1.11±0.4** 5 
α4L617Cβ2 120±7 4 10.84±2* 3±0.21** 4 
α4L617Fβ2 80±12 6 16.5±5* 1.21±0.2** 7 
α4F606Aβ2 51±12*** 4 2.32±0.08*** 3.8±1.2** 5 
α4F606Cβ2 131±8* 5 1.81±0.3* 4.01±1.4** 5 
β2 TMD 3 α4β2Y300A 43±3*** 3 6±3* 4.3±2* 3 
α4β2F303A 30±1.2*** 5 8±2* 3.4±0.4* 4 
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Table 2. Concentration effects of ACh and dFBr on α4β2 nAChRs containing alanine 
substitutions on residues of the β2 ECD. The concentration efects of dFBr were determined on 
ACh responses elicited by EC10 ACh concentrations. The data points were used to generate concentration response curves from which EC50, Hil coeficient (nH) (not shown) and maximal potentiation by dFBr of ACh EC10 current responses (Imax pot.) were estimated, as described in 
Experimental Procedures. Maximal potentiation by dFBr of ACh EC10 curent responses (Imax pot) was calculated as (IACh EC10 + dFBr) /IACh EC10.Values represent the mean ± SEM of n number of 
experiments. Al residues mutated to alanine and tested for functional efects on dFBr potentiation are 
predicted to lie within loops A, B or C of the ECD of the β2 subunit. None of the parameters 
estimated from the concentration response curves for DFBr were statisticaly diferent from their wild 
type counterparts (one-way ANOVA with Dunnet’s corection). However, ACh EC50 values were shifted to the right with mutations Y120A, D217A and D218A producing significant shifts (*, p < 
0.05). Of note, residues Y120 and W176 have been proposed to contribute to a potentiating dFBr-
binding site (22).  
 
 
 
 
ECD Loop 
Receptor ACh dFBr 
EC50 
(µM) 
n EC50 
(µM) 
Imax pot n 
α4β2 100± 7 20 1.33±0.03 10.6±2.0 15 
A α4β2Y120A 156± 36* 3 0.91±0.3 7.7±3 3 
B α4β2W176A 188± 31 5 1.61±0.09 7.8±2 3 
α4β2T177A 113± 12 4 1.12±0.1 6.7±2 3 
C α4β2Y221A 118± 15 3 1.11±0.1 12.8±2 3 
α4β2D217A 146± 22* 3 2.0±0.7 8.54±2 3 
α4β2D218A 138± 22* 4 2.1±0.2 10.12±2 3 
α4β2S219A 116± 10 4 1.7±0.3 9.8±2 3 
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Table 3. The Cys loop and post-M4 are necessary for dFBr potentiation of α4β2 nAChRs. EC50, values were estimated from ACh or dFBr concentration response curves, as described in Experimental 
Procedures. Maximal potentiation by dFBr of ACh EC10 current responses (Imax pot) was calculated as (IACh EC10 + dFBr) /IACh EC10.Values are expressed as the mean ± SEM on number of experiments. Statistical diferences were determined using one-way ANOVA with Dunnet’s corection. Asteriks 
denote levels of statistical diferences: *, p < 0.05; **, p < 0.001. 
 
Receptor 
 
ACh 
 
  dFBr 
EC50 (µM) 
n EC50 (µM) 
Imax pot n 
α4β2 100± 7 20 1.33±0.03 10.6±2.0 15 
α4(α3β1-β2 loop)β2 115± 16 5 1.81±0.3 8.8±3 6 
α4F167Aβ2 142± 15* 4 1.6±0.5 1.1 ±0.05** 8 
α4F170Aβ2 86±14 6 3.4±0.5** 1.8±0.09** 8 
α4F168Lβ2 89±21 3 0.59±0.07 14.7±2 4 
α4-PM4β2 118± 12 8 ND 1±0.07** 4 
α4LMAREDAβ2 121± 15 6 ND 1.05±0.09** 5 
α4W621Aβ2 107±20 3 1.7±0.4 7.6±2 5 
α4L622Aβ2 101±26 3 2.0±0.8 9.1±3 4 
α4M625Aβ2 110±15 3 1.9±0.4 5.7±1 6 
α4I626Aβ2 115±10 3 ND 1.01±0.2** 6 
α4AAWLAGMIβ2 126±12 3 ND 1.03±0.01** 5 
α4APWLAGMIβ2 133±17 5 7.7±1*** 1.3±0.02** 4 
α4PAWLAGMIβ2 121±12 5 ND 1.1±0.09** 6 
α4QPWLAGMIβ2 125±10 4 ND 1.3±0.09** 4 
α4F170Iβ2 122±10 6 6.6±2** 2.3±0.23* 9 
α4I626Fβ2 108±17 3 1.76±0.09 2.1±0.16* 7 
α4F170I-I626Fβ2 110±25 6 3.5±0.9* 5.4±0.38** 9 
α4F167Lβ2 91±15 4 2.94±0.8 10.82±0.42 5 
α4L305Fβ2 104±23 4 ND 1±0.1** 6 
α4F167L-L305Fβ2 125±22 5 ND 1±0.09** 7 
α4Y309Fβ2 115±5 3 0.4±0.1 2.75±0.3* 7 
α4F167Yβ2 95±9 3 1.4±0.2 2.2±0.17* 9 
α4F167Y-Y309Fβ2 115±20 5 1.82±0,1 11.32±0.4 6 
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Table 4. Functional effects of βEST on ACh responses of α4β2 nAChRs. EC50, Hil slope (not 
shown) and maximal potentiation by βEST (IβEST max pot) were estimated from concentration response 
curves, as described in Experimental Procedures. IβEST max pot of ACh EC10 current was calculated as (IACh EC10 + βEST) /IACh EC10.Values represent the mean ± SEM of n number of experiments. Statistical 
diferences were determined using one-way ANOVA with Dunnet’s correction. Asteriks show levels 
of statistical diferences: * p < 0.05; **, p < 0.001.  
 
nACh 
subunit 
ACh β-Estradiol 
EC50 (µM) 
n EC50 (µM) 
 IβEST max post n 
α4β2 100± 7 20 10.54±4 1.58±0.09 5 
α4Y309Aβ2 116±19 8 12±5 1.48±0.3 3 
α4F312Aβ2 102±6 15 13±5 1.51±0.2 4 
α4L617Aβ2 118±18 4 ND 1±0.07** 5 
α4Y309Fβ2 116±19 8 13.88±5 1.52±0.06 4 
α4F167Aβ2 142± 15* 5 12.56±4 1.54±0.1 3 
α4F167Yβ2 95±9 4 12.71±5 1.51±0.5 3 
α4F170Aβ2 86±14 4 11.5±0.5  
1.01±0.09** 
 
3 
α4F170Iβ2 122±10 4 ND 1.03±0.09** 4 
α4I626Aβ2 110±15 4 ND 1.01±0.05** 3 
α4I626Fβ2 108±17 4 ND 1.06±0.03** 4 
α4F167Y,Y309Fβ2 115±20 5 13.33±18 1.41±0.2 4 
α4F170I-I626Fβ2 110±25 5 10.1±18 1.3±0.2 4 
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FIGURE LEGENDS 
 
Figure 1. Effects of βEST and dFBr on alternate α4β2 nAChRs. A) Structure of 17β-Estradiol 
(βEST). B) Concentration response efects of βEST on the ACh EC10 curent responses of (α4β2)2α4 
and (α4β2)2β2 nAChRs. Data points represent the mean ± SEM of at least 4 experiments. The data were fit to the monophasic Hil equation, as described in Experimental Procedures. The efects of 
βEST were determined on ACh currents evoked by EC10 (3 µM for (α4β2)2β2) nAChRs and 10 µM 
for (α4β2)2α4 nAChRs.  C) Structure of desformylflustrabromine (dFBr); D) Potentiating efects of dFBr on the ACh responses of alternate (α4β2)2α4 and (α4β2)2β2 nAChRs. The concentration-
responses curves were obtained as for those of βEST. Data points represent the mean ± SEM of 5 
experiments. For B and D, functional expression of (α4β2)2α4 or (α4β2)2β2 nAChRs was achieved by expressing the concatenated forms of the alternate stoichiometries of the α4β2 nAChRs in Xenopus 
oocytes, as described under Experimental Procedures.  
 
Figure 2. M3 and M4 residues in the α4 nAChR subunit impact dFBr potentiation. A) Ful 
model of (α4β2)2α4 with α4 in yelow and β2 in blue on the left and a zoom on the potential dFBr site 
on the right. Residues that might be involved in binding dFBr are shown as sticks. dFBr is shown in 
light blue. B) Superimposition of the X-ray structure of (α4β2)2β2 nAChR onto the homology model used in this study to predict the binding site for dFBr in the α4β2 nAChR. The homology model is 
shown in yelow and the X-ray structure in grey. Relevant residues are shown as sticks (dark pink in 
the homology model and grey in the X-ray structure). C) Representative current responses elicited by 
ACh EC10 in the absence or presence of dFBr from oocytes expressing mutant α4Y309Aβ2, α4F312Aβ2 or α4L617Aβ2 nAChRs. D) Maximal dFBr potentiation of ACh EC10 curent responses from wild type or mutant (α4β2)2α4 or (α4β2)2β2 nAChRs. The alternate stoichiometries of the α4β2 
nAChR were expressed using concatemeric constructs, as described in Experimental Procedures. 
Maximal potentiation by dFBr of ACh EC10 curent responses (Imax pot) was calculated as (IACh EC10 + 
dFBr) /IACh EC10 from concentration response curve data, as described in Experimental Procedures. Values represent the mean ± SEM of at least 5 independent experiments. Asterisks indicate that the 
change in Imax pot. is statisticaly significant (**, p < 0.001, ***, p < 0.0001), as measured by one-way 
ANOVA with Dunnet’s correction. Doted line indicates a potentiation ratio of 1 (no potentiation). 
The cartoon underlying each column show how many copies of F312A (black dot) are present in the 
receptors. Red doted line indicates a potentiation ratio of 1 (no potentiation). 
 
Figure 3. Effects of MTSET on dFBr potentiation of α4β2 nAChRs. A) Representative curent 
traces from α4F617Cβ2 receptors showing potentiation of ACh EC10 currents before and after a 2 min application of 1 mM MTSET. B) Scater plot showing changes in dFBr potentiation after MTSET 
application to wild type or mutant α4β2 nAChRs containing α4L617C or α4F316C subunits. The 
percentage of change in dFBr potentiation was estimated using the equation: % Change = (Iafter /Iinitial) 
– 1) x 100), where Iinitial is the response to ACh EC10 + dFBr EC100 prior to MTSET application and 
Iafter is the response to ACh EC10 + dFBr EC100 after MTSET application. Asterisks indicate values that are significantly diferent from wild type (*, p < 0.05; ***, p < 0.0001). C) Representative traces 
showing the rate of MTSET (20 µM) reaction with L617C in the absence or presence of EC100 dFBr 
(10 µM). D) For protection assays using α4F617Cβ2 mutant receptors, the observed decreases in 
dFBr potentiation were ploted versus cumulative MTSET exposure in α4F617Cβ2 receptor. Data 
obtained from individual assays were normalised to the potentiation measured at t = 0 and fit to a 
single-exponential decay curve, as described in Experimental Procedures. (●, MTSET alone; ■, 
MTSET + dFBr). Data points are the means ± SEM from at least three independent assays. Asterisks 
indicate values that are significantly diferent from wild type (***, p < 0.0001). 
 
Figure 4. Mutations in Cys loop affect dFBr effects on nAChRs. A) Sequence alignment of the 
agonist-binding-channel gating coupling elements β1-β2 and Cys loop, M3 and M4 transmembrane α-
helices and the post-M4 region of nAChR α and β2 subunits. Residues that impact dFBr potentiation 
in α4β2 nAChRs are highlighted in bold. As shown in the alignment, these residues are conserved in 
the nAChR family. The post-M4 region is highlighted for al the sequences aligned. Unlike, the 
residues of the β1-β2, Cys loop and M3, M4 and post-M4 are highly variable in the nAChR family 
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(1). Sequences were aligned using the T-Cofee sequence alignment tool. B) Concentration-response 
curve for dFBr on wild-type α3β2 nAChRs (●) or α3F310Aβ2 (■) nAChRs. Data points represent the 
mean ±SEM of at least 4 experiments. The data were fit to the monophasic Hil equation, as described 
in Experimental Procedures. Inset shows representative ACh current responses traces of wild type or 
mutant α3β2 nAChRs in the absence or presence of increasing dFBr concentrations (10 μM, 30 µM 
and 100 μM). C) Maximal dFBr potentiation of ACh EC10 current from wild type and β1-β2 or Cys loop mutant α4β2 receptors. dFBr potentiation was calculated as (I(ACh EC10 + dFBr)/IACh EC10). 
Dashed line indicates wild type levels of potentiation and doted line indicates a potentiation ratio of 1 
(no potentiation). Asterisks indicate values that are significantly diferent from wild type (**, p < 
0.001). 
 
Figure 5. Post-M4 is a critical determinant of dFBr potentiation. A) Maximal efects of dFBr on 
wild type and mutant α4β2 nAChRs. Mutations were introduced individualy on α4 post-M4. dFBr 
potentiation was calculated as I(ACh EC10 + dFBr)/IACh EC10. Data are the mean ± SEM from at 
least three oocytes from two or more batches. Dashed line indicates wild type levels of potentiation, 
whilst the doted line indicates a potentiation ratio of one (no potentiation). Asterisks indicate values 
that are significantly diferent from wild type (**, p < 0.001). B) Representative traces of the maximal 
efects of dFBr on α3PPWLAGMIβ2 nAChRs. α3 subunit in wild type receptors has a longer and 
more hydrophilic post-M4 (LMAREDA). Wild type α3β2 receptors are insensitive to potentiation by 
dFBr (see Figure 3B). C) Concentration-response curves for the efects of dFBr on post-M4 mutants 
of the α3β2 nAChR. The post-M4 domain of the α3 subunit was changed to that of the α4 subunit, 
first keeping the α3 PQ motif preceding post-M4 (α3PQWLAGMI) and then substituting PQ for the 
PP motif found in the α4 subunit (α3PPWLAGMI). F310A efects on the efects of dFBr on 
α3PPWLAGMIβ2 receptors was also determined. Data were fit by non-linear regression as described 
in Experimental Procedures. 
 
Figure 6. Cys loop and post M4 interactions affect dFBr potentiation. A) Homology model of 
α4β2 showing the Cys loop and adjacent M3, M4 and post-M4 regions of a α4 subunit. Note that PP 
and post-M4 are shown to be helical because the homologous region in the template used (5-HT3 X-
ray structure) was found to be helical (36); however, the PP motif most likely disturbs the helicity. 
Also, note that only the PPWL motif of post-M4 (blue cartoon) is included in the model as the 
template was missing for the later four residues of post-M4, the AGMI motif. B-D). Representative 
current responses elicited by ACh EC10 traces in the presence and absence of EC100 dFBr from α4β2 nAChRs containing the folowing mutant α4 subunits:  α4F170I, α4I626F, α4F170I-I626F (B); 
α4F167Y, α4L305F, α4F167L-L305F (C); α4F167Y, α4Y309F and β4F167Y-Y309E) α4β2 nAChRs 
(D). E) Histogram of peak EC10 ACh currents in the presence of dFBr obtained from oocytes 
expressing wild type or mutant (α4F170I, α4I626F, α4F170I-I626F, α4F167Y, α4Y309F and 
β4F167Y-Y309E) α4β2 nAChRs. Data represent the mean ± SEM of at least three independent 
experiments. Statistical significance was determined by one-way ANOVA with a Dunnet’s post-test. 
*, p < 0.05; *** p < 0.001. Dashed line indicates wild type level of dFBr potentiation and doted line 
indicates a potentiation ratio of 1 (no response). 
 
Figure 7. Cys loop and post-M4 interactions affect βEST potentiation. A and B) Representative 
traces of ACh current responses in the presence and absence of EC100 βEST from wild type and mutant receptors. The mutant α4 subunits tested were as folows: A) α4F170I, α4I626F, α4F170I-
I626F and; B) α4F167Y, α4Y309F and β4F167Y-Y309E. C) Histogram of peak EC10 ACh currents in 
the presence of EC100 βEST obtained from oocytes expressing wild type or mutant (α4F170I, α4I626F, 
α4F170I-I626F, α4F167Y, α4Y309F and β4F167Y-Y309E) α4β2 nAChRs. Data represent the mean ± 
SEM of at least three independent experiments. Statistical significance was determined by one-way 
ANOVA with a Dunnet’s post-test. **, p < 0.001. Dashed line shows wild type level of βEST 
potentiation and doted line indicates a potentiation ratio of one (no potentiation). 
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